
Eli Lilly Buys Calytrix Bio in Up to $1.5B Blood Cancer Push
Unpacking Lilly's Calytrix acquisition: up to $1.5 billion in cash, milestone-linked payments and an early-stage rare blood cancer antibody that shows the Zepbound maker spreading its bets beyond obesity.




